Biotech RadarJobs updated

COMPANY

Terremoto Biosciences

HQ: South San Francisco, CA source · terremotobio.com ↗ · West Coast

Clinical Phase 2

1 open job · last seen Oct 23, 2026 · 3 sources

Profile checked Oct 10, 2026

Keywords: Breast Cancer Endometrial Cancer Ovarian Cancer Lung Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma Cervical Cancer Hereditary Hemorrhagic Telangiectasia TER-1754 TER-2013

1Open jobs2Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Join Terremoto's Talent NetworkSouth San FranciscoOct 18, 2024Oct 9, 2026

See all 1 job

Funding and NIH signals

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Raises announced in these releases: $458M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

  1. Board tracked Radar started tracking this company’s job board (1 open job at last check). source ↗
  2. Raise Series C · $108M source ↗
  3. Trial start Phase 1: A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia source ↗
  4. Trial start 1: A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations source ↗
  5. Raise Series B · $175M source ↗
  6. Raise Series B · $175M source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 1

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Join Terremoto's Talent NetworkSouth San FranciscoOct 18, 2024Oct 9, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT07109726A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations1RecruitingSep 23, 2025Dec 30, 2028 (estimated)
NCT07255846A Trial of TER-1754 in Patients With Hereditary Hemorrhagic TelangiectasiaPhase 1WithdrawnDec 15, 20252028-03 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback